July 29: Collaborative Care in Advanced NMSC

Target Audience 

This educational activity will address identified knowledge and practice gaps among community-based dermatologists, Mohs surgeons, radiation oncologists, community oncologists, and dermatology nurse practitioners and physician assistants.  

Learning Objectives 

Upon completion of this activity, participants should be better able to:

• Utilize the appropriate NMSC staging system so that patients at high risk of tumor progression are identified early in their course and can receive the most effective treatment.
• Describe the clinical trial efficacy and safety data of ICIs FDA-approved for the treatment of advanced cSCC and BCC.
• Incorporate the approaches to prevention, monitoring, and management of irAEs associated with immunotherapy.
• Develop strategies to improve multidisciplinary care coordination between dermatologists and oncology specialists. 

Program Overview 

Advanced nonmelanoma skin cancer (NMSC), including cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC), represents a growing clinical challenge for community dermatologists, who often lack experience identifying high-risk disease, navigating rapidly evolving immunotherapy data, and coordinating care with oncology teams. BRIDGE ONCOLOGY is an accredited continuing medical education (CME) initiative that connects community dermatologists with local medical oncology experts, with the goal of equipping clinicians to identify, stage, and appropriately refer patients with advanced NMSC earlier, and with greater confidence. 

Agenda 

• Introduction
• Management of advanced cSCC
• Management of advanced BCC
• Immune-related adverse events 

Physician Accreditation Statement 

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Credit Designation 

Integritas designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions to Receive Credit 

In order to receive credit for this activity, the participant must complete the pretest, pass the posttest with a 70% score or higher, and submit an evaluation form. 

Fee Information 

There is no fee for this activity. 

Disclosures of Conflicts of Interest 

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.   

All relevant financial relationships have been mitigated.  

The faculty have the following relevant financial relationships with ineligible companies: 

Jessica Kalen, MD, FAAD: 

• Nothing to disclose 

Vishal Anil Patel, MD: 

• Consulting Fees: Almirall S.A., Biofrontera, Palvella Therapeutics Inc, Regeneron Pharmaceuticals Inc, Replimune, Sun Pharmaceutical Industries Ltd 
• Speakers’ Bureau: Almirall S.A., Regeneron Pharmaceuticals Inc, Sun Pharmaceutical Industries Ltd
• Ownership Interest: Verrica Pharmaceuticals Inc 

The Integritas planners and managers have reported no relevant financial relationships with ineligible companies: 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.   

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Contact Information  

For information about this activity, please contact us at info@exchangecme.com